Novogen’s recent market updates presented mixed news for investors. Recruitment in the Cantrixil Phase I is underway and preparations for the Phase II trial of GDC-0084 in glioblastoma are progressing well, although headline data are now likely in…
May 25, 2017 at 05:35PM
from
No comments:
Post a Comment